Previous 10 | Next 10 |
ANN ARBOR, Mich., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Seth H.Z. Fischer as a Class III director, with a term expiring at the 2022 meeting of stockholders. "On behalf of the Esperion team and our directors, I am very pleased to w...
Esperion continues to struggle to get NEXLETOL and NEXLIZET off the launch pad as COVID-19 headwinds disrupt their commercial efforts. The lackluster launch and relentless cash burn has crushed the share price to all-time lows. The cost cutting should help reduce the need for crus...
Esperion Therapeutics (NASDAQ: ESPR) had a day to forget on Monday as its stock lost more than 11% on news that a fresh stack of shares would be coming to the market. Esperion announced Monday morning that it has entered into a private agreement with two holders of its convertib...
Gainers: IceCure Medical (NASDAQ:ICCM) +15%, Kiromic BioPharma KRBP +12%, Eargo (NASDAQ:EAR) +12%, Context Therapeutics (NASDAQ:CNTX) +11%, Xeris Biopharma XERS +11%. Losers: ERYTECH Pharma ERYP -39%, Eyenovia EYEN -37%, Es...
ANN ARBOR, Mich., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a privately negotiated exchange agreement with two co-managed holders (the “Holders”) of its 4.00% Convertible Senior Subordinated Notes due 2025 (the "Notes")....
– Optimizes organizational structure and operational processes to enable growth as the Company anticipates an inflection post the read-out of the CLEAR Outcomes trial – – Reduces overall workforce by 40 percent and further shifts marketing strate...
Favorable economic news and strong earnings figures helped spark a substantial rally on Thursday, with the S&P 500 scoring its best single-day performance in seven months. Dow component Salesforce.com Inc. (NYSE:CRM) used the tailwind to extend its recent gains, pushing to new 52-week hig...
ANN ARBOR, Mich., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report third quarter 2021 financial results before the open of the U.S. financial markets on Tuesday, November 2, 2021. Following the release, company management will host a webcast an...
ANN ARBOR, Mich., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), the lipid management company, today announced that it will host an investor webinar on the current landscape and future directions in the treatment of elevated cholesterol on Monday, September 13, 2021 at 1:30pm E...
Esperion (ESPR) recently reported mixed Q2 earnings with a beat on EPS and miss on revenue. The earnings were not enough for the market and ESPR continues lower. The company revealed that NEXLETOL and NEXLIZET had a strong quarter with a 67% increase in net revenue and a 28% increase ...
News, Short Squeeze, Breakout and More Instantly...
Esperion Therapeutics Inc. Company Name:
ESPR Stock Symbol:
NASDAQ Market:
Esperion Therapeutics Inc. Website:
– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) – – Animated Characters Are a Visual Representation of An Unseen Risk “Lurking” In Patients’ Artery Walls &...
– OMERS Life Sciences to Purchase Esperion’s European Royalty on Bempedoic Acid Products for $304.7 Million with European Royalties Reverting to Esperion Once OMERS Receives 1.7 Times its Investment – – Esperion Retains Rights to Receive all Poten...